Generic Drugs
•15 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (15)
%
| Company | Market Cap | Price |
|---|---|---|
|
Direct sale and distribution of generic drugs, a major CVS drug category.
|
$98.55B |
$77.90
-0.33%
|
|
The company has a robust generic drugs program and distributes generic pharmaceuticals, a core revenue stream in its Pharma segment.
|
$37.44B |
$156.88
-0.61%
|
|
Teva is a leading generic drug manufacturer with a broad portfolio and ongoing growth in generic sales.
|
$22.95B |
$20.01
+0.05%
|
|
Dr. Reddy's is a leading producer of generic drugs with a broad, global portfolio.
|
$11.96B |
$14.34
+1.63%
|
|
Viatris is a leading manufacturer of generic drugs with a diversified portfolio of off-patent medicines.
|
$11.17B |
$9.52
-0.42%
|
|
The company faces generic competition for Korlym and has an authorized generic, highlighting relevance to the generic drugs investing theme.
|
$7.84B |
$73.96
-15.51%
|
|
Core business: Amneal's primary revenue driver is generic medicine manufacturing (Affordable Medicines).
|
$3.12B |
$9.97
-3.11%
|
|
Generic Drugs is a core revenue driver for ANI with multiple new product launches and CGT-related exclusivity driving the Generics & Other segment.
|
$1.99B |
$90.17
-1.51%
|
|
Generic Drugs: Amphastar's legacy injectable generics (e.g., glucagon, epinephrine, enoxaparin) align with a generic drug portfolio.
|
$1.11B |
$23.63
-5.52%
|
|
Acquiring generic drug technologies suggests a strategy to develop or distribute generic drugs in parallel with ITV-1, aligning with a Generic Drugs theme.
|
$109.82M |
$0.32
|
|
Elite manufactures generic pharmaceutical products across CNS and other therapeutic areas (generic drugs).
|
$18.36M |
$0.63
+0.13%
|
|
The Marley Drug platform is expanding access to generic medications (e.g., Brenzavvy, sitagliptin generic), fitting Generic Drugs.
|
$7.83M |
$0.75
|
|
SBFM operates a Canadian generic prescription drug business (Nora Pharma) with multiple marketed generic drugs, making generic drugs a core revenue driver.
|
$7.06M |
$1.55
-6.63%
|
|
China Pharma Holdings focuses on generic drug production, fitting the generic drugs investable theme.
|
$6.17M |
$1.89
-2.07%
|
|
Is the sole US manufacturer of a generic sodium iodide I-131 drug product; fits the Generic Drugs category.
|
$518499 |
$0.05
-7.75%
|
Loading industry metrics...
Loading comparison data...
